000766 Stock Overview
Engages in the research, development, manufacture, and sale of pharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥15.45 |
| 52 Week High | CN¥20.20 |
| 52 Week Low | CN¥12.12 |
| Beta | 0.30 |
| 1 Month Change | 6.26% |
| 3 Month Change | -6.53% |
| 1 Year Change | -21.97% |
| 3 Year Change | 222.55% |
| 5 Year Change | 135.16% |
| Change since IPO | 155.23% |
Recent News & Updates
Recent updates
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd's (SZSE:000766) Popularity With Investors Is Under Threat From Overpricing
Aug 20
Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766) Seems To Use Debt Quite Sensibly
Jun 03Should You Be Adding Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766) To Your Watchlist Today?
May 12Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (SZSE:000766) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected
Mar 06Shareholder Returns
| 000766 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.4% | -1.8% | -1.7% |
| 1Y | -22.0% | -8.0% | 7.0% |
Return vs Industry: 000766 underperformed the CN Pharmaceuticals industry which returned -8% over the past year.
Return vs Market: 000766 underperformed the CN Market which returned 7% over the past year.
Price Volatility
| 000766 volatility | |
|---|---|
| 000766 Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.2% |
| 10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 000766 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 000766's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Hongjun Zhan | www.thjm.cn |
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical products in China. Its products covers anti-tumor, microbial, cardiovascular, heat-clearing and detoxification, digestive system, skeletal muscle system, gynecological system, nervous system, and other fields. The company also provides bone peptides, protective chemical medicines, cardiovascular and cerebrovascular chinese patent medicines, heat-clearing and detoxifying medicines, and children's respiratory system chinese patent medicines; and Xiaojin pills, Tian Ranshexiang Xiaojin pills, Xiaokechuan capsules, Jiuwei Qianghuo granules, Bear Bile powder, and Wenweishu tablets to treat glandular hyperplasia, inflammatory diseases, bone trauma and soft tissue injury, and other related diseases.
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Fundamentals Summary
| 000766 fundamental statistics | |
|---|---|
| Market cap | CN¥14.93b |
| Earnings (TTM) | CN¥33.24m |
| Revenue (TTM) | CN¥1.50b |
449.3x
P/E Ratio9.9x
P/S RatioIs 000766 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 000766 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.50b |
| Cost of Revenue | CN¥361.86m |
| Gross Profit | CN¥1.14b |
| Other Expenses | CN¥1.11b |
| Earnings | CN¥33.24m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 18, 2025
| Earnings per share (EPS) | 0.034 |
| Gross Margin | 75.90% |
| Net Profit Margin | 2.21% |
| Debt/Equity Ratio | 73.1% |
How did 000766 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 23:17 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Min Qiu | China Merchants Securities Co. Ltd. |